1、 HYPERLINK https:/www.MedChemE/Targets/PD-1_PD-L1.html PD-1/PD-L1PD-1/Programmed death-ligand 1Programmed death-1 (PD-1) is a cell surface receptor that functions as a T cell checkpoint and plays a central role in regulating Tcell exhaustion. PD-1 is activated by the engagement of its ligands PDL-1

2、or PDL-2. PD-1 receptor delivers inhibitory checkpointsignals to activated T cells upon binding to its ligands PD-L1 and PD-L2 expressed on antigen-presenting cells and cancer cells,resulting in suppression of T-cell effector function and tumor immune evasion. Inhibiting the programmed cell death-1(

3、PD-1)/programmed cell death-ligand 1 (PD-L1) pathway is an attractive strategy for tumor immunotherapy.PD-1 is expressed on activated T cells, B cells, monocytes, dendritic cells (DCs), regulatory T cells (Tregs), and natural killer T cells(NKT). It is a member of a family of immunoglobulin domain (

4、Ig) co-receptors that modify the outcome of activation of the T cellreceptor by an antigen-presenting cell (APC) or infected target cell. PD-L1 is widely and constitutively expressed on bothhematopoietic and nonhematopoietic cells; e.g., naive T and B cells, vascular endothelial cells, and pancreati

5、c islet cells, whereasPD-L2 is exclusively and inducibly expressed on professional APCs.www.MedChemE 1 HYPERLINK https:/www.MedChemE/Targets/PD-1/PD-L1.html PD-1/PD-L1 HYPERLINK https:/www.MedChemE/Targets/PD-1/PD-L1.html HYPERLINK https:/www.MedChemE/Targets/PD-1/PD-L1.html Inhibitors, HYPERLINK ht

6、tps:/www.MedChemE/Targets/PD-1/PD-L1.html HYPERLINK https:/www.MedChemE/Targets/PD-1/PD-L1.html Antagonists HYPERLINK https:/www.MedChemE/Targets/PD-1/PD-L1.html HYPERLINK https:/www.MedChemE/Targets/PD-1/PD-L1.html & HYPERLINK https:/www.MedChemE/Targets/PD-1/PD-L1.html HYPERLINK https:/www.MedChem

7、E/Targets/PD-1/PD-L1.html Activators HYPERLINK https:/www.MedChemE/arb-272572.html ARB-272572Cat. No.: HY-142221 HYPERLINK https:/www.MedChemE/Anti-PD-L1_Neutralizing_Antibody.html Atezolizumab(MPDL3280A) Cat. No.: HY-P9904ARB-272572 is a potent small-molecule PD-L1inhibitor with an IC value of 400p

8、M.50Atezolizumab (MPDL3280A) is a selective humanizedmonoclonal IgG1 antibody against programmed deathligand 1 (PD-L1), used for cancer research.Purity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mgPurity: 98.98%Clinical Data: LaunchedSize: 1 mg, 5 mg, 25 mg, 50 mg HYPERLINK https:/www.M

9、edChemE/np-12.html AUNP-12(NP-12) Cat. No.: HY-P1812 HYPERLINK https:/www.MedChemE/np-12-tfa.html AUNP-12 HYPERLINK https:/www.MedChemE/np-12-tfa.html HYPERLINK https:/www.MedChemE/np-12-tfa.html TFA(NP-12 TFA) Cat. No.: HY-P1812AAUNP-12 (NP-12) is a peptide antagonist of thePD-1 signaling pathway,

10、displays equipotentantagonism toward PD-L1 and PD-L2 in rescue oflymphocyte proliferation and effector functions.AUNP-12 TFA (NP-12 TFA) is a peptide antagonist ofthe PD-1 signaling pathway, displaysequipotent antagonism toward PD-L1 and PD-L2 inrescue of lymphocyte proliferation and effectorfunctio

11、ns.Purity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mgPurity: 96.0%Clinical Data: No Development ReportedSize: 1 mg, 5 mg, 10 mg HYPERLINK https:/www.MedChemE/Avelumab.html Avelumab HYPERLINK https:/www.MedChemE/Avelumab.html (Anti-Human PD-L1, Human Antibody; MSB 0010718C;MSB0010718C)

12、 Cat. No.: HY-108730 HYPERLINK https:/www.MedChemE/PD1-PDL1-inhibitor-1.html BMS-1(PD-1/PD-L1 inhibitor 1) Cat. No.: HY-19991Avelumab is a fully human IgG1 anti-PD-L1monoclonal antibody with potentialantibody-dependent cell-mediated cytotoxicity.BMS-1 is an inhibitor of the PD-1/PD-L1protein/protein

13、 interaction (IC between 6 and 10050nM).Purity: 98%Clinical Data: LaunchedSize: 1 mg, 5 mg, 10 mgPurity: 99.56%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg HYPERLINK https:/www.MedChemE/bms-1001-hydrochloride.html BMS-1001 HYPERLINK https:/www.MedChemE/bm

14、s-1001-hydrochloride.html HYPERLINK https:/www.MedChemE/bms-1001-hydrochloride.html hydrochloride HYPERLINK https:/www.MedChemE/bms-1001-hydrochloride.html HYPERLINK https:/www.MedChemE/BMS-1166.html BMS-1166Cat. No.: HY-120635 Cat. No.: HY-102011BMS-1001 hydrochloride is an orally active humanPD-L1

15、/PD-1 immune checkpoint inhibitor. BMS-1001hydrochloride exhibits low-toxicity in cells.BMS-1166 is a potent PD-1/PD-L1 immune checkpointinhibitor. BMS-1166 induces dimerization of PD-L1and blocks its interaction with PD-1, with an IC50of 1.4 nM. BMS-1166 antagonizes the inhibitoryeffect of PD-1/PD-

16、L1 immune checkpoint on T cellactivation.Purity: 98.46%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mgPurity: 98.37%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg HYPERLINK https:/www.MedChemE/bms-1166-hydrochloride

17、.html BMS-1166 HYPERLINK https:/www.MedChemE/bms-1166-hydrochloride.html HYPERLINK https:/www.MedChemE/bms-1166-hydrochloride.html hydrochloride HYPERLINK https:/www.MedChemE/bms-1166-hydrochloride.html HYPERLINK https:/www.MedChemE/BMS-202.html BMS-202Cat. No.: HY-102011A Cat. No.: HY-19745BMS-1166

18、 hydrochloride is a potent PD-1/PD-L1immune checkpoint inhibitor. BMS-1166hydrochloride induces dimerization of PD-L1 andblocks its interaction with PD-1, with an IC of501.4 nM.BMS-202 is a potent and nonpeptidic PD-1/PD-L1complex inhibitor with an IC of 18 nM and a50K of 8 M. BMS-202 binds to PD-L1

19、 and blocksDhuman PD-1/PD-L1 interaction. BMS-202 hasantitumor activity.Purity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mgPurity: 99.39%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg2 Tel: 609-228-6898 Fax: 609-228-5909 Email: salesMedChemE H

20、YPERLINK https:/www.MedChemE/bms-8.html BMS-8 HYPERLINK https:/www.MedChemE/bms-8.html HYPERLINK https:/www.MedChemE/bmspep-57.html BMSpep-57Cat. No.: HY-116274 Cat. No.: HY-P3143BMS-8 inhibits the PD-1/PD-L1 interaction withIC of 7.2 M. BMS-8, binds directly to PD-L1 and50induces formation of PD-L1

21、 homodimers, which inturn prevents the interaction with PD-1.BMSpep-57 is a potent and competitive macrocyclicpeptide inhibitor of PD-1/PD-L1 interaction withan IC of 7.68nM. BMSpep-57 binds to PD-L150with K s of 19 nM and 19.88 nM in MST anddSPR assays,respectively.Purity: 98%Clinical Data: No Deve

22、lopment ReportedSize: 1 mg, 5 mgPurity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mg HYPERLINK https:/www.MedChemE/bmspep-57-hydrochloride.html BMSpep-57 HYPERLINK https:/www.MedChemE/bmspep-57-hydrochloride.html HYPERLINK https:/www.MedChemE/bmspep-57-hydrochloride.html hydrochloride H

23、YPERLINK https:/www.MedChemE/bmspep-57-hydrochloride.html HYPERLINK https:/www.MedChemE/L-Threonine,_N-_1S_-3-amino-1-3-_1R_-1-amino-2-hydroxyethyl-1,2,4-oxadiazol-5-yl-3-oxopropylaminocarbonyl-.html CA-170Cat. No.: HY-P3143A Cat. No.: HY-101093BMSpep-57 hydrochloride is a potent andcompetitive macr

24、ocyclic peptide inhibitor ofPD-1/PD-L1 interaction with an IC of 7.68nM.50BMSpep-57 hydrochloride binds to PD-L1 with K sdof 19 nM and 19.88 nM in MST and SPR assays,respectively.CA-170 is an orally delivered dual inhibitor ofVISTA and PD-L1. CA-170 exhibits potent rescue ofproliferation and effecto

25、r functions of T cellsinhibited by PD-L1/L2 and VISTA with selectivityover other immune checkpoint proteins as well as abroad panel of receptors and enzymes.Purity: 99.79%Clinical Data: No Development ReportedSize: 1 mgPurity: 96.26%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 1 mg, 5 mg,

26、 10 mg, 25 mg, 50 mg, 100 mg HYPERLINK https:/www.MedChemE/camrelizumab.html Camrelizumab(SHR-1210) Cat. No.: HY-P9971 HYPERLINK https:/www.MedChemE/d18.html D18Cat. No.: HY-144501Camrelizumab (SHR-1210) is a potent humaniedhigh-affinity IgG4- monoclonal antibody (mAb) toPD-1. Camrelizumab binds PD-

27、1 at a highaffinity of 3 nM and inhibits the bindinginteraction of PD-1 and PD-L1 with an IC of 0.7050nM.D18 is an immune modulator. D18 acts as a TLR7/8dual agonist (EC =24 nM for hTLR7 and 10 nM for50hTLR8, respectively). D18 increases PD-L1expression through epigenetic regulation, thussensitizing

28、 tumors to PD-1/PD-L1 blockade.Purity: 97.70%Clinical Data: No Development ReportedSize: 1 mg, 5 mgPurity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mg HYPERLINK https:/www.MedChemE/durvalumab.html Durvalumab HYPERLINK https:/www.MedChemE/durvalumab.html HYPERLINK https:/www.MedChemE/pd

29、-1-pd-l1-in-7.html Evixapodlin(MEDI 4736) Cat. No.: HY-P9919 (PD-1/PD-L1-IN 7) Cat. No.: HY-138407Durvalumab (MEDI 4736) is an humanized anti-PD-L1monoclonal antibody. Durvalumab (MEDI4736)completely blocks the binding of PD-L1 to bothPD-1 and CD80, with IC s of 0.1 and 0.04 nM,50respectively.Evixap

30、odlin (PD-1/PD-L1-IN 7) is a humanPD-1/PD-L1 protein/protein interaction inhibitorwith an IC of 0.213 nM. Evixapodlin has50anticancer and antiviral functions.Purity: 99.60%Clinical Data: LaunchedSize: 1 mg, 5 mg, 25 mg, 50 mgPurity: 98.48%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg,

31、 10 mg, 25 mg, 50 mg HYPERLINK https:/www.MedChemE/fraxinellone.html Fraxinellone HYPERLINK https:/www.MedChemE/fraxinellone.html HYPERLINK https:/www.MedChemE/he-s2.html HE-S2Cat. No.: HY-N0242 Cat. No.: HY-144497Fraxinellone is isolated from the root bark of theRutaceae plant, Dictamnus dasycarpus

32、.Fraxinellone is a PD-L1 inhibitor and inhibitsHIF-1 protein synthesis without affecting HIF-1protein degradation.HE-S2 is an antibody-drug conjugate triggering apotent antitumor immune response. HE-S2 acts byblocking the PD-1/PD-L1 interaction andactivating the Toll-like receptor 7/8 (TLR7/8)signal

33、ing pathway. HE-S2 has remarkable antitumoractivity.Purity: 99.99%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 20 mgPurity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mgwww.MedChemE 3 HYPERLINK https:/www.MedChemE/human-pd-l1-inhibitor-ii.html Human HYPERLINK http

34、s:/www.MedChemE/human-pd-l1-inhibitor-ii.html HYPERLINK https:/www.MedChemE/human-pd-l1-inhibitor-ii.html PD-L1 HYPERLINK https:/www.MedChemE/human-pd-l1-inhibitor-ii.html HYPERLINK https:/www.MedChemE/human-pd-l1-inhibitor-ii.html inhibitor HYPERLINK https:/www.MedChemE/human-pd-l1-inhibitor-ii.htm

35、l HYPERLINK https:/www.MedChemE/human-pd-l1-inhibitor-ii.html II HYPERLINK https:/www.MedChemE/human-pd-l1-inhibitor-ii.html HYPERLINK https:/www.MedChemE/human-pd-l1-inhibitor-iii.html Human HYPERLINK https:/www.MedChemE/human-pd-l1-inhibitor-iii.html HYPERLINK https:/www.MedChemE/human-pd-l1-inhib

36、itor-iii.html PD-L1 HYPERLINK https:/www.MedChemE/human-pd-l1-inhibitor-iii.html HYPERLINK https:/www.MedChemE/human-pd-l1-inhibitor-iii.html inhibitor HYPERLINK https:/www.MedChemE/human-pd-l1-inhibitor-iii.html HYPERLINK https:/www.MedChemE/human-pd-l1-inhibitor-iii.html IIICat. No.: HY-P2470 Cat.

37、 No.: HY-P2564Human PD-L1 inhibitor II is a potent PD-L1inhibitor with anti-cancer activity.Human PD-L1 inhibitor III is a human PD-L1inhibitor.Purity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mgPurity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mg HYPERLINK https:/www.MedC

38、hemE/human-pd-l1-inhibitor-iv.html Human HYPERLINK https:/www.MedChemE/human-pd-l1-inhibitor-iv.html HYPERLINK https:/www.MedChemE/human-pd-l1-inhibitor-iv.html PD-L1 HYPERLINK https:/www.MedChemE/human-pd-l1-inhibitor-iv.html HYPERLINK https:/www.MedChemE/human-pd-l1-inhibitor-iv.html inhibitor HYP

39、ERLINK https:/www.MedChemE/human-pd-l1-inhibitor-iv.html HYPERLINK https:/www.MedChemE/human-pd-l1-inhibitor-iv.html IV HYPERLINK https:/www.MedChemE/human-pd-l1-inhibitor-iv.html HYPERLINK https:/www.MedChemE/human-pd-l1-inhibitor-v.html Human HYPERLINK https:/www.MedChemE/human-pd-l1-inhibitor-v.h

40、tml HYPERLINK https:/www.MedChemE/human-pd-l1-inhibitor-v.html PD-L1 HYPERLINK https:/www.MedChemE/human-pd-l1-inhibitor-v.html HYPERLINK https:/www.MedChemE/human-pd-l1-inhibitor-v.html inhibitor HYPERLINK https:/www.MedChemE/human-pd-l1-inhibitor-v.html HYPERLINK https:/www.MedChemE/human-pd-l1-in

41、hibitor-v.html VCat. No.: HY-P2477 Cat. No.: HY-P2478Human PD-L1 inhibitor IV, a polypeptide, is acompetitive human PD-1 protein inhibitor with aK value of 1.38 M. Human PD-L1 inhibitor IVdinhibits the interaction of hPD-1/hPD-L1.Human PD-L1 inhibitor V, a human PD-1 proteinbinding peptide with a K

42、value of 3.32 M.dHuman PD-L1 inhibitor V inhibit the interaction ofhPD-1/hPD-L1.Purity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mgPurity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mg HYPERLINK https:/www.MedChemE/human-pd-l1-inhibitor-v-tfa.html Human HYPERLINK https:/www

43、.MedChemE/human-pd-l1-inhibitor-v-tfa.html HYPERLINK https:/www.MedChemE/human-pd-l1-inhibitor-v-tfa.html PD-L1 HYPERLINK https:/www.MedChemE/human-pd-l1-inhibitor-v-tfa.html HYPERLINK https:/www.MedChemE/human-pd-l1-inhibitor-v-tfa.html inhibitor HYPERLINK https:/www.MedChemE/human-pd-l1-inhibitor-

44、v-tfa.html HYPERLINK https:/www.MedChemE/human-pd-l1-inhibitor-v-tfa.html V HYPERLINK https:/www.MedChemE/human-pd-l1-inhibitor-v-tfa.html HYPERLINK https:/www.MedChemE/human-pd-l1-inhibitor-v-tfa.html TFACat. No.: HY-P2478A HYPERLINK https:/www.MedChemE/pd-1-pd-l1-in-8.html INCB086550(PD-1/PD-L1-IN

45、-8) Cat. No.: HY-134884Human PD-L1 inhibitor V TFA, a human PD-1protein binding peptide with a K value of 3.32dM. Human PD-L1 inhibitor V TFA inhibit theinteraction of hPD-1/hPD-L1.INCB086550 (PD-1/PD-L1-IN-8; example 24) is aPD-1/PD-L1 inhibitor, with an IC 98%Clinical Data: No Development Reported

46、Size: 1 mg, 5 mg HYPERLINK https:/www.MedChemE/Anti-PD-1_Neutralizing_Antibody_2.html Nivolumab HYPERLINK https:/www.MedChemE/Anti-PD-1_Neutralizing_Antibody_2.html HYPERLINK https:/www.MedChemE/onvatilimab.html Onvatilimab(BMS-936558; ONO-4538; MDX-1106) Cat. No.: HY-P9903 (JNJ-61610588) Cat. No.:

47、HY-P99040Nivolumab is a programmed death receptor-1 (PD-1)blocking human IgG4 antibody to treat advanced(metastatic) non-small cell lung cancer.Onvatilimab (JNJ-61610588) is a human IgG1anti-VISTA (V-domain Ig Suppressor of T-cellActivation) monoclonal antibody. Onvatilimab has ananti-tumor activity

48、.Purity: 98.56%Clinical Data: LaunchedSize: 1 mg, 5 mg, 25 mg, 50 mgPurity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mg4 Tel: 609-228-6898 Fax: 609-228-5909 Email: salesMedChemE HYPERLINK https:/www.MedChemE/pd-1-in-17.html PD-1-IN-17 HYPERLINK https:/www.MedChemE/pd-1-in-17.html HYPER

49、LINK https:/www.MedChemE/pd-1-in-17-tfa.html PD-1-IN-17 HYPERLINK https:/www.MedChemE/pd-1-in-17-tfa.html HYPERLINK https:/www.MedChemE/pd-1-in-17-tfa.html TFACat. No.: HY-101097 Cat. No.: HY-101097APD-1-IN-17 is a programmed cell death-1 (PD-1)inhibitor extracted from patent WO2015033301A1,Compound

50、 12, inhibits 92% splenocyte proliferationat 100 nM.PD-1-IN-17 TFA is a programmed cell death-1(PD-1) inhibitor extracted from patentWO2015033301A1, Compound 12, inhibits 92%splenocyte proliferation at 100 nM.Purity: 95.0%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 25 mg, 50

51、 mg, 100 mgPurity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mg HYPERLINK https:/www.MedChemE/PD1-IN-2.html PD-1-IN-18 HYPERLINK https:/www.MedChemE/PD1-IN-2.html HYPERLINK https:/www.MedChemE/pd-1-in-20.html PD-1-IN-20Cat. No.: HY-101098 Cat. No.: HY-101093BPD-1-IN-18 is a PD1 signalin

52、g pathway inhibitor,which acts as an immunomodulator.PD-1-IN-20 is the less active enantiomer ofPD-1-IN-1. PD-1-IN-1 is an inhibitor of programmedcell dealth-1 (PD-1) extracted from patent WO2015033299 A1, compound example 4.Purity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mgPurity: 98

53、%Clinical Data: No Development ReportedSize: 1 mg, 5 mg HYPERLINK https:/www.MedChemE/pd-1-in-22.html PD-1-IN-22 HYPERLINK https:/www.MedChemE/pd-1-in-22.html HYPERLINK https:/www.MedChemE/pd-1-in-24.html PD-1-IN-24Cat. No.: HY-128605 Cat. No.: HY-134886PD-1-IN-22 is a potent programmed cell death-1

54、(PD-1)/programmed cell death-ligand 1 (PD-L1)interaction inhibitor with an IC of 92.3 nM.50PD-1-IN-24 (compound 1) is an orally active PD-1inhibitor.Purity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mgPurity: 98.04%Clinical Data: No Development ReportedSize: 10 mM 1 mL, 5 mg, 10 mg, 25

55、mg, 50 mg, 100 mg HYPERLINK https:/www.MedChemE/pd-1-pd-l1-in-3.html PD-1/PD-L1-IN HYPERLINK https:/www.MedChemE/pd-1-pd-l1-in-3.html HYPERLINK https:/www.MedChemE/pd-1-pd-l1-in-3.html 3 HYPERLINK https:/www.MedChemE/pd-1-pd-l1-in-3.html HYPERLINK https:/www.MedChemE/pd-1-pd-l1-in-3-tfa.html PD-1/PD

56、-L1-IN HYPERLINK https:/www.MedChemE/pd-1-pd-l1-in-3-tfa.html HYPERLINK https:/www.MedChemE/pd-1-pd-l1-in-3-tfa.html 3 HYPERLINK https:/www.MedChemE/pd-1-pd-l1-in-3-tfa.html HYPERLINK https:/www.MedChemE/pd-1-pd-l1-in-3-tfa.html TFACat. No.: HY-103048 Cat. No.: HY-103048APD-1/PD-L1-IN 3, a macrocycl

57、ic peptide, is apotent and selective inhibitor of the PD-1/PD-L1and CD80/PD-L1 interactions extracted from patentWO2014151634A1, compound No.1.PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is apotent and selective inhibitor of the PD-1/PD-L1and CD80/PD-L1 interactions extracted from patentWO2014151634

58、A1, compound No.1.Purity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mgPurity: 98%Clinical Data: No Development ReportedSize: 1 mg, 5 mg HYPERLINK https:/www.MedChemE/pd-1-pd-l1-in-5-1.html PD-1/PD-L1-IN HYPERLINK https:/www.MedChemE/pd-1-pd-l1-in-5-1.html HYPERLINK https:/www.MedChemE/p

59、d-1-pd-l1-in-5-1.html 5 HYPERLINK https:/www.MedChemE/pd-1-pd-l1-in-5-1.html HYPERLINK https:/www.MedChemE/pd-1-pd-l1-in-5.html PD-1/PD-L1-IN HYPERLINK https:/www.MedChemE/pd-1-pd-l1-in-5.html HYPERLINK https:/www.MedChemE/pd-1-pd-l1-in-5.html 5 HYPERLINK https:/www.MedChemE/pd-1-pd-l1-in-5.html HYP

60、ERLINK https:/www.MedChemE/pd-1-pd-l1-in-5.html TFACat. No.: HY-129172A Cat. No.: HY-129172PD-1/PD-L1-IN 5 is a PD-1/PD-L1 protein/proteininteraction inhibitor extracted from patentWO2017222976A1, compound Example 1, has an IC of50100 nM.PD-1/PD-L1-IN 5 TFA is a PD-1/PD-L1protein/protein interaction